Our Products

HLS Therapeutics Inc. offers a portfolio of products that meet and exceed the stringent quality and safety requirements of the US Food and Drug Administration and Health Canada. Our primary treatment areas are psychiatric disorders and cardiovascular risk reduction. Demand for psychiatric treatments is projected to grow substantially over the next decade due to rising diagnoses, an aging population, decreased stigmatization of mental health care, and innovation in pharmaceutical sciences. Similarly, increases in diagnosed stressors, cardiovascular diseases, and an aging population are expected to increase the market for effective cardiovascular therapies. Below is an overview of our therapeutics and their status in the United States and Canada.

HLS Therapeutics Product Portfolio

Product Portfolio

Product Portfolio

Vascepa Vascepa logo Cardiovascular (CV) risk reduction Flag of Canada Marketed
Clozaril Clozaril logo US Treatment-Resistant Schizophrenia Flag of United States Marketed
Clozaril Clozaril logo Canada Treatment-Resistant Schizophrenia Flag of Canada Marketed
CSAN Pronto White Blood Cells (WBC) Point-of-Care Diagnostic Flag of Canada Marketed
MyCare Psychiatry Psychiatric Therapeutic Drug Monitoring Flag of Canada Marketed
Royalty Portfolio Multiple Indications Global Icon Marketed by third parties
Health Stewards Logo (opens in new window)

We are proud to support Medications Return Programs managed by Health Products Stewardship Association (HPSA). These programs provide a safe and convenient way for consumers to dispose of unused or expired medications in an environmentally responsible manner. To learn more about properly storing and handling pharmaceuticals or finding a collection location near you, we encourage you to visit the HPSA website at www.healthsteward.ca (opens in new window)

Returned Goods Policy